Evidence map›Paper›PMID 27653359›Full record

ArticleMemorias do Instituto Oswaldo Cruz2016

Mechanisms of carbapenem resistance in endemic Pseudomonas aeruginosa isolates after an SPM-1 metallo-β-lactamase producing strain subsided in an intensive care unit of a teaching hospital in Brazil.

Luciana Camila Cacci, Stephanie Gomes Chuster, Natacha Martins, Pâmella Rodrigues do Carmo, Valéria Brígido de Carvalho Girão, Simone Aranha Nouér, Wania Vasconcelos de Freitas, Juliana Arruda de Matos, Ana Cristina de Gouveia Magalhães, Adriana Lúcia Pires Ferreira and 2 more

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2024
    Review
  4. Review
  5. Article
  6. Genomics and Antimicrobial Susceptibility of ClinicalPathogens (Basel, Switzerland) · 2023
    Article
  7. Review
  8. Evaluation ofNew microbes and new infections · 2021
    Article
  9. Review
  10. Article
  11. Plasmid CarryingAntimicrobial agents and chemotherapy · 2019
    Article
  12. Article
  13. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Luciana Camila CacciUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Stephanie Gomes ChusterUniversidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Microbiologia, Rio de Janeiro, RJ, Brasil.
Natacha MartinsUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Pâmella Rodrigues do CarmoUniversidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Microbiologia, Rio de Janeiro, RJ, Brasil.
Valéria Brígido de Carvalho GirãoUniversidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Microbiologia, Rio de Janeiro, RJ, Brasil.
Simone Aranha NouérUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Wania Vasconcelos de FreitasUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Juliana Arruda de MatosUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Ana Cristina de Gouveia MagalhãesUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Adriana Lúcia Pires FerreiraUniversidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro, RJ, Brasil.
Renata Cristina PicãoUniversidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Microbiologia, Rio de Janeiro, RJ, Brasil.
Beatriz Meurer MoreiraUniversidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Microbiologia, Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistance mechanisms are a challenge in the treatment of Pseudomonas aeruginosa infections. We investigated changes in P. aeruginosa carbapenem-resistance determinants over a time period of eight years after the emergence of São Paulo metallo-β-lactamase in a university hospital in Rio de Janeiro, Brazil. Patients admitted to the intensive care unit (ICU) were screened for P. aeruginosa colonisation and followed for the occurrence of infections from April 2007 to April 2008. The ICU environment was also sampled. Isolates were typed using random amplified polymorphic DNA, pulsed-field gel electrophoresis and multilocus sequence typing. Antimicrobial susceptibility was determined by disk diffusion and E-test, production of carbapenemases by a modified-CarbaNP test and presence of carbapenemase-encoding genes by polymerase chain reaction. Non-carbapenemase resistance mechanisms studied included efflux and AmpC overexpression by PAβN and cloxacillin susceptibility enhancement, respectively, as well as oprD mutations. From 472 P. aeruginosa clinical isolates (93 patients) and 17 isolates from the ICU environment, high genotypic diversity and several international clones were observed; one environment isolate belonged to the blaSPM-1 P. aeruginosa epidemic genotype. Among isolates from infections, 10 (29%) were carbapenem resistant: none produced carbapenemases, three exhibited all non-carbapenemase mechanisms studied, six presented a combination of two mechanisms, and one exclusively displayed oprD mutations. Carbapenem-resistant P. aeruginosa displayed a polyclonal profile after the SPM-1 epidemic genotype declined. This phenomenon is connected with blaSPM-1 P. aeruginosa replaced by other carbapenem-resistant pathogens.

Indexed as

Anti-Bacterial Agentsbeta-Lactamasesbeta-Lactam ResistanceCarbapenemsDisk Diffusion Antimicrobial TestsDNA, BacterialElectrophoresis, Gel, Pulsed-FieldGenotypeHospitals, UniversityHumansIntensive Care UnitsMultilocus Sequence TypingPolymerase Chain ReactionProspective StudiesPseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial Agentsbeta-Lactamasesbeta-lactamase SPM-1, Pseudomonas aeruginosaCarbapenemsDNA, Bacterial

Identifiers

PMID27653359
PMCPMC5027862
OpenAlexW2520805146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.